Video Series

Learn how tailored meds, diet, exercise, and cholesterol control help prevent repeat ischemic stroke—while balancing bleeding risk and adherence.

Experts reveal gaps in stroke detection, follow‑up and prevention, plus a simple “MATH” guide to hemorrhagic causes and blood pressure goals.

Seventy percent of participants rated total symptom clearance as very important—higher than any other treatment attribute, including speed of response or convenience. How does this align with what dermatologists have traditionally defined as treatment success?

Rising urine albumin signals higher heart and kidney risk; learn how better screening, EHR prompts, and new therapies can transform CKD care.

Discover the stroke care team—from primary care to rehab—plus proven prevention steps and the high stakes of recurrent stroke.

Stroke subtypes vary widely, but prevention is clear: control blood pressure, diabetes, cholesterol, exercise, quit smoking, and cut disability costs.

A retrospective analysis comparing 3-year psoriatic arthritis incidence across immunomodulatory classes finds an emerging signal favoring IL-23 pathway agents—a finding with meaningful implications for treatment selection in patients at risk for joint disease.

The panelist explored the following critical questions: What systems-level strategies can improve coverage readiness for new metabolic dysfunction-associated steatohepatitis (MASH) treatments? What system-wide transformations are necessary to sustain scalable, multidisciplinary MASH care? What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

In this episode, 'System-Level Barriers and Evidence Gaps in the Adoption of Emerging MASH Therapies,' the expert hepatologist explored the following questions: What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Rising urine albumin signals hidden kidney and heart risk; learn why earlier UACR/eGFR screening and new therapies can change CKD outcomes.

An analysis of the POSITIVE study showed that tildrakizumab not only clears skin but substantially reduces itch, pain, and fatigue, with psychological well-being scores ultimately surpassing general population norms by year 2.

Across a landmark guideline update, a primary prevention trial, and the first treat-to-target proof of concept, the message is consistent: lower LDL for longer saves lives—and achieving that goal in practice demands goals, teams, tools, and lifestyle as the foundation.

Even with a treat-to-target protocol, only 61% of Ez-PAVE participants reached goal—but the trial's broader lesson is that combination therapy and equitable access to newer agents are the path to closing the gap.

Welcome back to another AJMC Insights series. In this episode titled, ‘Addressing the Challenges of Undiagnosed Chronic Kidney Disease’, Manisha Jhamb led the conversation

The POSITIVE study's 2-year real-world data confirm that tildrakizumab drives near-total skin clearance and sustained improvement in difficult-to-treat areas, lending important practical validity to the phase 3 trial results.

Ez-PAVE delivers the first direct trial evidence that targeting LDL below 55 mg/dL is superior to below 70 mg/dL in ASCVD patients—providing proof of concept for treat-to-target strategies and a wake-up call about clinical inertia.

Long-acting therapies could be key to engaging unsuppressed patients and closing persistent gaps in HIV care.

Landmark analyses from VESALIUS-CV reveal that the cardiovascular benefits of intensive LDL lowering build meaningfully over time in primary prevention—reinforcing the "lower for longer" principle and pointing toward lower LDL targets for high-risk diabetic patients.

Panelists examine the societal impact of stroke by outlining its prevalence, underlying pathophysiology, key modifiable risk factors, and the substantial clinical, economic, and long-term disability burden it places on patients and the healthcare system.

Panelists explore stroke classification and clinical presentation, highlighting key differences between ischemic and hemorrhagic strokes, the TOAST system for subtype identification, and the importance of understanding underlying causes to guide diagnosis and long-term management.

A phase 3b trial demonstrates that tildrakizumab meets robust efficacy endpoints for nail psoriasis—an historically difficult manifestation to treat—while maintaining a favorable long-term safety profile through week 72.

VESALIUS-CV shows that evolocumab delivers a 31% relative risk reduction in major cardiovascular events in high-risk diabetic patients without established atherosclerosis—making a compelling case for intensive LDL lowering well before a first event.

Beyond standard risk scores, the guideline highlights key risk enhancers—including lipoprotein(a), inflammation markers, and women's health factors—and elevates coronary artery calcium scoring as a Class I tool for resolving uncertainty in primary prevention.

Long-acting CAB+RPV may maintain efficacy even with delayed injections, offering real-world flexibility.

For the first time, the 2026 ACC/AHA guideline provides strong, evidence-based recommendations for patients who cannot tolerate statins—a group historically underserved by prior guidance. Outcome data now support bempedoic acid (from the CLEAR trial), PCSK9 monoclonal antibodies, ezetimibe, and inclisiran as viable alternatives. Rather than defaulting to high-intensity statin doses, clinicians can consider combination strategies such as a moderate-intensity statin paired with ezetimibe—a pairing shown in the RACING trial to match the cardiovascular event reduction of high-intensity monotherapy while improving tolerability and LDL goal achievement. The "rule of sixes"—where doubling a statin dose yields only an additional 6% LDL reduction versus 18% from adding ezetimibe—further reinforces early combination thinking.

The 2026 update to the ACC/AHA guideline for dyslipidemia management represents a meaningful shift in how and when clinicians should begin lipid-lowering therapy, Erin D. Michos, MD, MHS, professor of medicine, director of Women's Cardiovascular Health and associate director of Preventive Cardiology in the Division of Cardiology at Johns Hopkins University School of Medicine, explains.

Chemotherapy sequencing in the ARPI era and the role of radiopharmaceuticals versus docetaxel remain unsettled, while genetics and PSMA-PET emerge as essential themes for community oncologists.

Benjamin Lockshin, MD, FAAD, offers a forward-looking synthesis of how psoriasis care has evolved toward holistic, personalized management—and where advances in oral therapies, biomarker-guided selection, and equitable access will define the next era of treatment.